Mir-19 medicine being developed in Russia to be effective against any Covid-19 variants - FMBA
MOSCOW. July 9 (Interfax) - A medicine being developed by Russia's Federal Medical-Biological Agency (FMBA) as treatment for Covid-19 will be effective against any of its variants, as it targets the most stable sites of the virus, FMBA head Veronica Skvortsova said on Friday.
"The sites of the virus's genome chosen as targets for the drug are highly conservative and are virtually not prone to mutations, and that is why they remain relevant for any of the known coronavirus variants, including the British and the Indian ones," the FMBA website quoted Skvortsova as saying.
Mir-19 is being developed as an antidote against the novel coronavirus, and its effect is based on the well-studied RNA interference mechanism, the FMBA press release said.
"With small interfering RNA as an active component, the medicine will specifically destroy a particular site of the virus's genome responsible for its replication (ability to reproduce itself)," it said.
In the course of experiments, Mir-19 reduced the virus's concentration in infected animals by 99.99%, according to the developers.
Phase 1 of Mir-19's clinical trials on humans was completed in March 2021 and confirmed its safety.
The developers assume that Mir-19's efficacy should be the highest within the first two to three days after a person is infected.
The medicine is currently undergoing Phase 2 of its clinical trials at FMBA centers in Moscow, the Moscow region, St. Petersburg, and the Leningrad region, which is expected to be completed in mid-August 2021. Once Mir-19's efficacy is proven, the FMBA will apply for its registration.
Skvortsova said in April that Mir-19 would be used only at hospitals some time after its registration. If the medicine is proven to be highly efficacious, the FMBA plans to develop two alternative spray forms as a post-contact prevention method. The medicine could be used to prevent an onset of the disease if a person had earlier contacted people infected with coronavirus.